Anupam Rasayan revenue grew 65% in FY26 as margins dropped to 23%
Revenue growth failed to offset margin compression, with Q4 profit dropping 11% year-on-year.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- FY26 revenue grew 65% compared to the previous year.
- EBITDA margins fell to 23% from 28%.
- Q4 profit after tax dropped 11% year-on-year.
Why this matters
Top-line expansion is losing quality as margins compress. The decline in Q4 profit suggests that recent acquisitions and deals have yet to translate into bottom-line growth.
What we're watching
- Whether margins recover in FY27 as new acquisitions integrate.
- Cost management efforts to reverse the margin slide.
- The impact of the Jayhawk and Bliss GVS Pharma deals on future earnings.
The full read
Anupam Rasayan reported 65% year-on-year revenue growth for FY26.
Margins are under pressure.
EBITDA margins slid to 23% from 28% a year earlier, and this compression hit the bottom line in the final quarter, where profit after tax dropped 11% year-on-year. While the company continues to integrate the Jayhawk acquisition and the Bliss GVS Pharma deal, these strategic moves have not yet shielded the firm from the broader margin decline. The core challenge for management is scaling revenue while the cost of doing business grows faster than the top line. The next test is margin stabilization in the coming quarters.
Questions answered
- How did Anupam Rasayan perform in FY26?
- The company reported a 65% year-on-year increase in revenue for the full fiscal year.
- What happened to the company's profitability?
- EBITDA margins declined to 23% from 28% in the previous year, and Q4 profit after tax dropped 11% year-on-year.
- Are there any new strategic developments in this release?
- No. The release mentions the Jayhawk acquisition and the Bliss GVS Pharma deal, both of which were disclosed in previous filings.
Story so far
All notes on ANURAS →- Today · 8:27 PM IST Anupam Rasayan revenue grew 65% in FY26 as margins dropped to 23%
- 1d ago Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore
- 1d ago Anupam Rasayan buys 74.20% stake in Bliss GVS Pharma